Under health secretary Robert F
Key Results Semaglutide vs Sitagliptin HR 0.58 (95% CI, 0.510.65) 42% lower risk 1-yr absolute risk: 5.5% vs 8.6% NNT 31 Tirzepatide vs Sitagliptin HR 0.42 (95% CI, 0.310.57) 58% lower risk 1-yr absolute risk: 3.6% vs 7.5% NNT 26 Tirzepatide vs Semaglutide HR 0.86 (95% CI, 0.701.06) no statistically significant difference Safety: No excess signal for GI, infections, or serious AEs across GLP-1/dual arms
When injected directly into a localised pocket of fat, the formulation disrupts the fat cell membrane and supports the release of the stored fat content
Your provider will set a personalized timeline based on your condition
Reduce inflammation: Chronic inflammation can hinder weight loss and contribute to metabolic dysfunction
6,9,15 What is the dose of Mounjaro